Insider Selling: Sangamo Therapeutics Inc (SGMO) VP Sells $163,260.00 in Stock

Sangamo Therapeutics Inc (NASDAQ:SGMO) VP Curt A. Herberts III sold 8,163 shares of the company’s stock in a transaction dated Friday, April 13th. The stock was sold at an average price of $20.00, for a total transaction of $163,260.00. Following the completion of the sale, the vice president now owns 22,788 shares in the company, valued at approximately $455,760. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

NASDAQ:SGMO opened at $19.20 on Friday. Sangamo Therapeutics Inc has a 52 week low of $4.05 and a 52 week high of $27.50. The company has a debt-to-equity ratio of 0.13, a quick ratio of 5.54 and a current ratio of 5.54. The company has a market cap of $1,685.77, a PE ratio of -27.43 and a beta of 2.80.

How to Become a New Pot Stock Millionaire

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.03. Sangamo Therapeutics had a negative net margin of 149.23% and a negative return on equity of 31.44%. The firm had revenue of $13.08 million for the quarter, compared to analysts’ expectations of $11.10 million. During the same quarter in the prior year, the company posted ($0.14) earnings per share. The business’s revenue for the quarter was up 46.6% on a year-over-year basis. equities analysts predict that Sangamo Therapeutics Inc will post -0.15 earnings per share for the current fiscal year.

A number of equities research analysts have weighed in on SGMO shares. BidaskClub cut shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 17th. Wedbush restated a “neutral” rating and issued a $6.00 price objective on shares of Sangamo Therapeutics in a report on Monday, February 12th. Barclays restated a “buy” rating and issued a $30.00 price objective on shares of Sangamo Therapeutics in a report on Sunday, February 25th. Zacks Investment Research cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 5th. Finally, Piper Jaffray set a $25.00 price target on shares of Sangamo Therapeutics and gave the company a “buy” rating in a report on Wednesday, January 3rd. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Sangamo Therapeutics has a consensus rating of “Buy” and an average target price of $20.83.

A number of institutional investors have recently modified their holdings of the stock. Raymond James Financial Services Advisors Inc. lifted its position in Sangamo Therapeutics by 29.3% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 18,962 shares of the biopharmaceutical company’s stock valued at $311,000 after purchasing an additional 4,300 shares during the period. Nationwide Fund Advisors lifted its position in Sangamo Therapeutics by 13.5% during the third quarter. Nationwide Fund Advisors now owns 44,892 shares of the biopharmaceutical company’s stock valued at $673,000 after purchasing an additional 5,337 shares during the period. Swiss National Bank lifted its position in Sangamo Therapeutics by 3.9% during the fourth quarter. Swiss National Bank now owns 142,460 shares of the biopharmaceutical company’s stock valued at $2,336,000 after purchasing an additional 5,400 shares during the period. California State Teachers Retirement System lifted its position in Sangamo Therapeutics by 5.0% during the third quarter. California State Teachers Retirement System now owns 132,741 shares of the biopharmaceutical company’s stock valued at $1,991,000 after purchasing an additional 6,360 shares during the period. Finally, Great West Life Assurance Co. Can lifted its position in Sangamo Therapeutics by 150.3% during the third quarter. Great West Life Assurance Co. Can now owns 12,767 shares of the biopharmaceutical company’s stock valued at $182,000 after purchasing an additional 7,667 shares during the period. Institutional investors own 64.69% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Sangamo Therapeutics Inc (SGMO) VP Sells $163,260.00 in Stock” was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/04/20/insider-selling-sangamo-therapeutics-inc-sgmo-vp-sells-163260-00-in-stock.html.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply